Ovarian Cancer

Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.

Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.

PARP inhibitor use increased regardless of BRCA mutation status.

Individualized niraparib dosing should be considered standard practice, according to researchers.

The results raise concern about potential local tumor spill, according to researchers.

There was no improvement in progression-free or overall survival.

Rucaparib prolonged progression-free survival.

There was an improvement in second progression-free survival, but not overall survival, with niraparib.